Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126646282 | 12664628 | 2 | F | 20160822 | 20160818 | 20160823 | EXP | TN-TEVA-685277ISR | TEVA | MELEK K, SONIA H, WALID B, LEILA N, RIM K, ABDELFATTEH Z. AUTOIMMUNE HEMOLYTIC ANEMIA REVEALING CLASSICAL HODGKIN LYMPHOMA: TWO CASE REPORTS AND LITERATURE REVIEW.PHILLIPPINE JOURNAL OF INTERNAL MEDICINE. 2016; 54(2) | 50.00 | YR | M | Y | 0.00000 | 20160823 | MD | TN | TN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126646282 | 12664628 | 1 | SS | DOXORUBICIN | DOXORUBICIN | 1 | 4 CYCLES | 0 | 25 | MG/M**2 | |||||||||
| 126646282 | 12664628 | 2 | SS | DOXORUBICIN | DOXORUBICIN | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 35 | MG/M**2 | |||||||||
| 126646282 | 12664628 | 3 | PS | ETOPOSIDE. | ETOPOSIDE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 74284 | 100 | MG/M**2 | |||||||||
| 126646282 | 12664628 | 4 | SS | VINCRISTINE | VINCRISTINE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 1.4 | MG/M**2 | |||||||||
| 126646282 | 12664628 | 5 | SS | BLEOMYCIN | BLEOMYCIN SULFATE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 10 | MG/M**2 | |||||||||
| 126646282 | 12664628 | 6 | SS | BLEOMYCIN | BLEOMYCIN SULFATE | 1 | 4 CYCLES | 0 | 15 | MG | |||||||||
| 126646282 | 12664628 | 7 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 1200 | MG/M**2 | |||||||||
| 126646282 | 12664628 | 8 | SS | DACARBAZINE. | DACARBAZINE | 1 | 4 CYCLES | 0 | 375 | MG/M**2 | |||||||||
| 126646282 | 12664628 | 9 | SS | VINBLASTINE | VINBLASTINE | 1 | 4 CYCLES | 0 | 10 | MG | |||||||||
| 126646282 | 12664628 | 10 | SS | PROCARBAZINE | PROCARBAZINE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 100 | MG | |||||||||
| 126646282 | 12664628 | 11 | C | PREDNISONE. | PREDNISONE | 1 | HIGH DOSES | 0 | 1 | MG/KG | |||||||||
| 126646282 | 12664628 | 12 | C | PREDNISONE. | PREDNISONE | 1 | ON DAY 1 AND DAY 8 (8 CYCLES) | 0 | 40 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126646282 | 12664628 | 1 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 2 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 3 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 4 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 5 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 6 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 7 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 8 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 9 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 10 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 11 | Hodgkin's disease mixed cellularity stage III |
| 126646282 | 12664628 | 12 | Hodgkin's disease mixed cellularity stage III |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126646282 | 12664628 | OT |
| 126646282 | 12664628 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126646282 | 12664628 | Drug ineffective | |
| 126646282 | 12664628 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |